Pharmaceutical Safety Review • High Interaction Classification

Clinical Analysis Prescription Drug Interactions & CYP450 Profile

Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.

Absolute Clinical Contraindications

  • Personal/family history of Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2
  • Pregnancy

Reported Clinical Adverse Events

  • Nausea (18%)
  • Constipation
  • Gastroesophageal reflux
  • Headache

Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

  • CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
  • Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
  • Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (4 – 6 hours).

Protocol Audit Links for Clinical Analysis

← Return to Clinical Analysis Monograph Calculate Weight Dosage Table → Launch Full Multi-Drug Interaction Checker →